Armen Shanafelt insider trades: Aeglea BioTherapeutics (AGLE) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Armen reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 13, 2021 | AGLE | ↑ Buy | 150,000 | $3.66 | $550K | Direct | Dec 13, 2021 (0d) |
| Apr 23, 2018 | SURF | ↑ Buy | 266,000 | $15.00 | $4.0M | Indirect | Apr 23, 2018 (0d) |
| Jul 5, 2017 | ALRN | ↑ Buy | 250,000 | $15.00 | $3.8M | Indirect | Jul 7, 2017 (2d) |
| Aug 16, 2016 | PTGX | ↑ Buy | 583,333 | $12.00 | $7.0M | By Fund | Aug 16, 2016 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Armen Shanafelt's insider trades
Armen Shanafelt is a director at Aeglea BioTherapeutics (AGLE). Since Aug 16, 2016, Armen has reported 4 open-market purchases worth $15.3M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (18 filings), conversions (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AGLE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.